Keith A. Josephs, M.D.

The purpose of this study is to learn more about the distribution of the pathological protein tau in the living brains of patients with Progressive Supranuclear Palsy (PSP).

This study is designed to learn more about the use of a new imaging agent AV-1451 which shows strong binding to abmormal tau in the brain, to see if it will allow positron emission tomography (PET) scanning of tau in the brains of patients with Primary Progressive Aphasia.

The purpose of this study is to perform longitudinal assessments in patients with neurodegenerative and related disorders to better understand the underlying cause/s which will help with the development of future treatments and prognosis.

The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

The purpose of this study is to identify biomarkers from patients with different neurodegenerative diseases including progressive supranuclear palsy, progressive apraxia of speech, primary progressive aphasia, semantic dementia, corticobasal syndrome, posterior cortical atrophy and others. These patients have a clinical diagnosis rendered for research but the underlying pathology is unknown.  

Brain autopsies will be performed in patients who have, or will be enrolled in any of NIH or foundation funded grants. 

The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.